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ABSTRACT
The clinical success of immune checkpoint inhibitors
has highlighted the central role of the immune system
in cancer control. Immune checkpoint inhibitors can
reinvigorate anti-cancer immunity and are now the
standard of care in a number of malignancies. However,
research on immune checkpoint blockade has largely been
framed with the central dogma that checkpoint therapies
intrinsically target the T cell, triggering the tumoricidal
potential of the adaptive immune system. Although T cells
undoubtedly remain a critical piece of the story, mounting
evidence, reviewed herein, indicates that much of the
efficacy of checkpoint therapies may be attributable to
the innate immune system. Emerging research suggests
that T cell-directed checkpoint antibodies such as anti-
programmed cell death protein-1 (PD-1) or programmed
death-ligand-1 (PD-L1) can impact innate immunity by
both direct and indirect pathways, which may ultimately
shape clinical efficacy. However, the mechanisms and
impacts of these activities have yet to be fully elucidated,
and checkpoint therapies have potentially beneficial and
detrimental effects on innate antitumor immunity. Further
research into the role of innate subsets during checkpoint
blockade may be critical for developing combination
therapies to help overcome checkpoint resistance.
The potential of checkpoint therapies to amplify innate
antitumor immunity represents a promising new field that
can be translated into innovative immunotherapies for
patients fighting refractory malignancies.

in the realm of antitumor immunity. Thus,
the scope of research into immune checkpoint blockade may have been limited by ‘T
cell centrism’. Growing evidence, reviewed
below, highlights the emerging appreciation
that innate immune cells mediate key aspects
of checkpoint therapy biology. Despite
numerous clinical successes, many patients
do not respond to checkpoint therapies,
and some cancer types are almost entirely
resistant. An improved understanding of the
mechanisms by which current checkpoint
inhibitors function will enable clinicians to
broaden the benefits of these treatments to
greater numbers of patients.

Keeping T cells in check
PD-1 and its ligands are central to regulating
inflammation and peripheral tolerance. PD-1-
null mice spontaneously develop a lupus-like
syndrome due in part to uncontrolled proliferation of autoreactive T cells.3 PD-1 restrains
T cell activity when engaged by its ligands,
PD-L1 and PD-L2.4 PD-L1 expression is inducible in a variety of cell types, including adaptive and innate immune cells, mesenchymal
cells, and cancer cells.4 In contrast, expression of PD-L2 is limited to antigen-presenting
cells (APCs) and a smaller subset of tumor
INTRODUCTION
cell types.4 PD-1/PD-L1 signaling profoundly
Cancer research was transformed with the modulates T cell cytokine secretion, dampens
discovery that tumor-specific T cell dysfunc- T cell receptor (TCR) signaling, and shortens
tion was reversible with immune checkpoint synapse engagement between T cells and
blockade.1 Antagonistic antibodies targeting
APCs, resulting in impaired antitumor
cytotoxic T-lymphocyte-associated protein immunity.5 PD-1/PD-
L1 blockade partially
4 (CTLA-4) and programmed cell death
reverses these negative effects, augmenting
protein-1 (PD-1) or programmed death- T cell proliferation, tumor infiltration, and
ligand-1 (PD-L1) stimulate antitumor immu- cytotoxicity.4
nity and are now approved therapies in many
CTLA-4 is another crucial T cell coincancer types, including metastatic melanoma hibitory receptor, which is upregulated in
and non-small cell lung cancer.2 These clin- activated T cells and natively expressed by
ical successes highlight the immense poten- regulatory T cells (Tregs).6 In resting T cells,
tial for T cell-
directed immunotherapy in
CTLA-4 is stored within cytosolic endosomes.6
cancer; however, we are just beginning to
After TCR engagement and costimulatory
understand the full molecular activity of signaling via CD28, CTLA-4 molecules transsuch agents. The remarkable achievements locate to the cell surface, where they outcomof these therapies in the clinic have elevated pete CD28 for its ligands, B7.1 and B7.2,
the T cell above all other immune lineages expressed in APCs, restraining proliferation
Liu X, et al. J Immunother Cancer 2021;9:e001460. doi:10.1136/jitc-2020-001460
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and activation of T cells.6 CTLA-4 has a non-redundant
immunosuppressive role; CTLA-4-deficient mice die at
1 month of age as a result of a lethal lymphoproliferative
disorder.7 In multiple models, CTLA-4 blockade results
in T cell-
mediated tumor rejection.1 These findings
spurred clinical trials that demonstrated the efficacy of
anti-CTLA-4 in multiple cancers as a single agent or in
combination with anti-PD-1.2
The impact of checkpoint inhibitors on innate immune cells
Over the last two decades, research on checkpoint inhibitors has focused on the T cell as the principal therapeutic target; however, recent studies have highlighted
the significant effects of checkpoint inhibitors on innate
immune cells. Checkpoint blockade has both a direct and
an indirect impact on innate immune lineages (figure 1).
In the indirect pathway, anti-PD-1/PD-L1 or anti-CTLA-4
reinvigorates T cell immunity, which, in turn, shapes or
phenotypically polarizes innate immune cell responses
within the tumor microenvironment (TME). In the
2

direct pathway, innate immune cells are direct targets
of immune checkpoint blockade because subtypes of
myeloid cells and innate lymphocytes express PD-1 and/
or PD-L1. This highly nuanced interplay of cell types after
checkpoint therapy testifies to the importance of investigating how checkpoint biology affects innate immune
populations.
Tumor-associated macrophages and other myeloid cells in
PD-1/PD-L1 checkpoint blockade
Indirect regulation
Macrophage function is orchestrated by activated T cells.8
T cell-
associated cytokines such as interferon gamma
(IFN-γ) stimulate macrophages to increase expression
of major histocompatibility complex (MHC) molecules,
costimulatory receptors, and the Th1-
polarizing cytokine IL-12.9 Accordingly, checkpoint blockade-activated
T cells dramatically alter phenotypes of tumor-associated
macrophages (TAMs) and monocytes. Gubin and
colleagues used single cell RNA-sequencing (scRNA-seq)
Liu X, et al. J Immunother Cancer 2021;9:e001460. doi:10.1136/jitc-2020-001460
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Figure 1 Direct and indirect regulation of innate immune subsets by PD-1 blockade. The regulation of innate immune cells
by PD-1 blockade is divided into direct (left) and indirect (right) pathways. In the direct pathway, PD-1 blockade reshapes the
phenotypes and functions of innate immune subsets, such as TAMs, DCs, MDSCs, NK cells, and ILC2s, expressing PD-1
(left). In the indirect pathway, T cells activated by anti-PD-1 secrete IFN-y, which in turn phenotypically polarizes myeloid cells
within the TME (right). Bold arrows indicate interactions. DCs, dendritic cells; IFN-y, interferon gamma; ILCs, innate lymphoid
cells; MDSCs, myeloid-derived suppressor cells: NK, natural killer cells; PD-1, programmed cell death protein 1; TAMs, tumor-
associated macrophages; TEM, tumor microenvironment.
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Direct regulation
Myeloid cells display detectable PD-1 levels.11 PD-1
expressing TAMs have been shown to promote tumor
progression in several cancers including gastric cancer,12
colorectal cancers,13 and lung cancer.14 The appearance
of PD-1 in myeloid progenitors is an early event in tumor
progression, as the receptor may be induced by inflammatory conditions.15 Indeed, bone marrow–derived macrophages (BMDMs) rapidly upregulate PD-1 after Toll-like
receptor (TLR)−2 engagement16; correspondingly, PD-1
was upregulated by macrophages in a murine model of
sepsis.17 The signaling downstream of PD-1 in macrophages is controversial and may be contextually dependent. PD-1-null BMDMs express more IL-6, and CCL2
(MCP-1) at 4-
hour post TLR2 stimulation, suggesting
an anti-inflammatory role of PD-1.16 In contrast, in vivo
evidence found the opposite effect. Septic PD-1-null mice
demonstrate decreased levels of peritoneal CCL2, tumor
necrosis factor-alpha (TNF-α), and IL-1β, an observation
that was abrogated on depletion of peritoneal macrophages.17 These in vivo data suggest that PD-1 expression on macrophages augments systemic inflammation.
Despite the lack of a clear signaling pathway downstream
of PD-1 in macrophages, there is a clear link between
TAM expressed PD-1 and cancer-
associated inflammation. In cancer models, synergistic antitumor effects were
found with the combination of PD-1/PD-
L1 blockade
and neutralization of either IL-618 or IL-1β,19 indicating
that targeting the inflammatory TME could amplify PD-1
blockade efficacy. This effect likely involves macrophage
expressed PD-1, as the authors found that PD-1 agonism
suppressed production of IL-6 by PD-1-
bearing TAMs,
whereas anti-PD-L1 enhanced IL-6 production.18 Thus,
anti-inflammatory therapies may be necessary for maximizing the benefit of checkpoint blockade. These data
suggest a complex role of myeloid intrinsic PD-1 signaling
and highlight the need to delineate the mechanistic
differences between PD-1 blockade and PD-1 deletion.
New model systems have permitted the investigation
of the myeloid-specific effects of checkpoint blockade.
Liu X, et al. J Immunother Cancer 2021;9:e001460. doi:10.1136/jitc-2020-001460

Strauss et al generated a mouse model in which PD-1
was selectively deleted in myeloid cells.15 The authors
employed these mice to dissect the relative contribution of myeloid versus T cell PD-1 signaling in colon
cancer.11 Interestingly, myeloid-specific PD-1 deletion was
as effective at limiting tumor growth as global PD-1 deletion, and more effective than selective ablation of PD-1
in T cells.15 One caveat to these studies is that genetic
approaches to interrupt PD-1/PDL-1 signaling may
not accurately model therapeutic antagonist therapies.
However, the authors treated Recombination Activating
Gene-2-null mice lacking T and B cells with anti-PD-1 and
still observed a significant reduction in tumor growth,15
again emphasizing the critical importance of the innate
immune system for checkpoint blockade.
PD-1 engagement on myeloid cells affects infiltration,
differentiation, effector function, and cellular metabolism. Some of these pathways and outcomes are highlighted in figure 2. PD-1 engagement shifts activated
human monocyte metabolism toward oxidative phosphorylation. PD-1/PD-L1 blockade is able to rescue glycolysis,
which is correlated with enhanced antibody-dependent
phagocytosis.20 PD-1-
deficient myeloid cells exhibit
altered development from common myeloid progenitors,
with diminished accumulation of granulocyte/macrophage progenitors in the bone marrow and increased
expansion of Ly6C+ monocytes and dendritic cells (DCs)
within the tumor.15 These data suggest that PD-1 signaling
in myeloid progenitors may direct myelopoiesis toward
the granulocytic lineage, resulting in greater numbers of
immunosuppressive granulocytic-MDSCs. These findings
suggest that checkpoint therapies may benefit from drug
combinations that limit tumor infiltration by myeloid
subsets. Regarding effector function, PD-1 expressing
TAMs demonstrate high levels of CD206, arginase 1
(ARG1), and IL-10, which dampen antitumor immune
responses.13 In contrast, PD-1 deficiency in TAMs shifts
their phenotype toward an antitumor profile, with higher
levels of TNFα, iNOS, and MHCII.21 In multiple cancer
models, TAM infiltration is skewed toward CD206+,
ARG1high macrophages22; however, anti-
PD-1 therapy
reverses this trend, increasing the expression of iNOS,
TNF-α, and IL-6, which may augment antitumor immunity.14 These findings corroborate the scRNA-seq results
of Gubin et al and strikingly highlight that at a transcriptomic level, checkpoint therapy has a concomitant, if not
greater, impact on TAM phenotype than on T cell phenotype. Together, these data suggest that PD-1 blockade
reprograms TAMs toward an antitumor phenotype.
Myeloid-specific effects of PD-L1 blockade
Canonically, PD-L1 interacts with its receptor PD-1 on
tumor-specific T cells and limits their antitumor activity.23
Anti-PD-L1 therapy blocks this interaction, thereby reinvigorating T cell proliferation and effector functions
such as IFN-γ secretion.24 However, like anti-PD-1, PD-L1
blockade can also directly and indirectly modulate myeloid
cell function. Anti-PD-L1 has been shown to indirectly
3
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and mass cytometry to assess transcriptional and functional changes in tumor-infiltrating myeloid cells after
treatment with anti-PD-1.10 PD-1 blockade resulted in a
reduction in CD206+ TAMs and an increase in inducible
nitric oxide synthase+ (iNOS+) TAMs.10 This INOS+ TAM
cluster was enriched for genes involved in IFN-γ signaling,
high glycolytic activity, and NF-κB activity, suggestive of
antitumor potential.10 Moreover, on IFN-γ neutralization,
anti-
PD-1-
mediated repolarization of TAMs/monocytes
was significantly diminished.10 These results demonstrate
the potential of checkpoint-activated T cells to secrete
factors, such as IFN-γ, that remodel the TME toward a
tumor hostile environment, rich in iNOS+ TAMS, which
are associated with improved outcomes in many tumor
models. Thus, anti-PD-1 can be added to a growing list
of therapies aimed at ‘repolarizing’ TAMs away from a
tumor permissive phenotype.

Open access

repolarize TAMs toward a proinflammatory phenotype,
in a T cell-dependent, IFN-γ-mediated process.25 These
anti-
PD-
L1-
treated TAMs exhibit decreased expression
of ARG1 and enhanced iNOS, MHCII, and CD40 expression, indicative of an antitumor phenotype.25 In the
direct pathway, TAMs can engage with activated T cells
expressing PD-
L1. T cell PD-
L1 binds TAM-
expressed
PD-1 and induces a tolerogenic phenotype.26 These findings indicate that anti-PD-L1 may disrupt multiple axes
of PD-1 engagement to restore the antitumor potential
of TAMs.
The bulk of research on anti-PD-L1 therapy emphasizes the disrupted interaction between tumor-expressed
PD-
L1 and T cell-
expressed PD-1. However, PD-
L1 is
widely inducible on immune subsets, tumor cells, and
even endothelial cells, in an IFN-γ-dependent process.27
Thus, both tumor and host PD-L1 are intimately involved
in checkpoint blockade.28 In some malignancies such as
colon cancer, tumor immune infiltrates express PD-L1
at significantly greater levels than tumor cells.29 Thus,
it is essential to study the role of tumor extrinsic PD-L1.
4

Indeed, PD-
L1 expressing lymph node resident APCs
can inhibit T cell activation and prevent recruitment of
primed T cells to the TME.30 PD-L1+ neutrophils have
been shown to impair T cell immunity in hepatocellular
carcinoma.31 In some models, PD-L1 expression by cancer
cells is dispensable for anti-PD-L1 efficacy.28 30 32 PD-L1
blockade efficacy was retained in a PD-L1-deficient model
of colon adenocarcinoma.30 However, efficacy was lost if
the bone marrow from PD-L1-null mice was transplanted
into tumor-bearing mice, indicating that a hematopoietic
cell was responsible for the response.30 The efficacy was
again lost after depleting CD11b+ PD-L1+ cells, presumably due to an absence of PD-L1-expressing APCs.30 These
data support the essential role of PD-L1+ myeloid cells
in anti-PD-L1 therapy. Other authors have disputed the
dispensable nature of tumor expressed PD-L1 and have
demonstrated that both tumor and APC expressed PD-L1
are involved in critical but distinct aspects of PD-1/PD-L1
blockade.28 32 These findings have broad implications
for the use of PD-L1 as a biomarker for checkpoint efficacy. Patients may benefit from separate quantification of
Liu X, et al. J Immunother Cancer 2021;9:e001460. doi:10.1136/jitc-2020-001460
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Figure 2 Direct and indirect signaling pathways downstream of PD-1 blockade in myeloid cells. PD-1 blockade results in
direct (left) and indirect (right) signaling outcomes. Direct PD-1 blockade in PD-1 expressing myeloid cells activates NF-κB and
pSTAT1 signaling pathways and reprograms glycometabolism (left). In the indirect pathway, anti-PD-1 activated T cells secrete
IFN-y which triggers NF-κB and pSTAT1 signaling pathways in myeloid cells (right). Arrows indicate downstream outcomes of
PD-1 blockade. IFN-γ, interferon gamma; PD-1, programmed cell death protein 1.
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Linking PD-1/PD-L1 blockade and DC function
Indirect regulation
The efficacy of PD-1 blockade may depend on the indirect
activation of tumor-infiltrating DCs. Anti-PD-1-activated
T cells secrete IFN-γ, which in turn sets in motion a
dramatic transcriptomic shift in DC phenotype, as they
express antigen presentation machinery, upregulating
IL-12, CCR7, MHCII, CD80, CD40, TLR-2, and TLR-4.36 37
CCR7 enables DC trafficking to tumor draining lymph
nodes, where DCs prime CD8 and CD4 T cell responses
via class I and II MHC and the costimulatory molecules
CD80/CD86.36 37 Signaling through CD40 and TLRs
further augments IL-12 production, which activates CD8
T cells and polarizes primed CD4 T cells toward the Th1
subset, which in turn secrete additional IFN-γ in a feed
forward loop.36–38 In summary, IFN-γ-stimulated DCs are
highly efficient APCs, specialized for priming in vivo T cell
responses. Recent studies have demonstrated that DCs
are also necessary for anti-PD-1 efficacy. In a fibrosarcoma
model, anti-
PD-1-
mediated tumor regression was lost
when DCs were depleted or when IL-12 was neutralized.38
Additionally, tumor-bearing mice with DCs expressing a
conditional mutation in the IFN-γ receptor demonstrate
profoundly depressed IL-12 production, and lose checkpoint responsiveness.38 Interestingly, these IL-12+ DCs
are enriched for non-canonical NF-κB signaling pathway
components, such as CD40, Nfkb2, and Relb.38 Indeed,
Liu X, et al. J Immunother Cancer 2021;9:e001460. doi:10.1136/jitc-2020-001460

inactivation of the non-canonical NF-κB pathway also abrogates checkpoint efficacy.38 These observations have motivated researchers to combine CD40 agonists with PD-1/
PD-L1 blockade due to potential synergy.38 Improving T
cell-DC crosstalk via non-canonical NF-κB signaling offers
the compelling possibility of converting the TME from
immunologically cold to checkpoint responsive.
Direct regulation
Although indirect regulation of DCs by anti-
PD-1 is
well established, evidence of direct regulation is still
emerging. Patients with hepatocellular carcinoma39 and
ovarian cancer40 have increased numbers of PD1-bearing
DCs, suggesting that the expression of PD-1 by DCs may
be context-dependent. Emerging evidence indicates that
PD-1 signaling in DCs may inhibit survival41 and decrease
secretion of IL-12 and TNF-α, suppressing the antitumor
potential of CD8+ T cells.42 PD-1 signaling in DCs also
engages the canonical NF-κB pathway and suppresses
antigen presentation machinery by blocking surface
expression of MHCI.40 43 In vivo models of hepatocellular
carcinoma support an immunosuppressive role for PD-1
in DCs. Specific ablation of PD-1 on intratumoral DCs
resulted in enhanced priming of tumor-specific CD8 T
cells, which exhibited increased expression of the cytolytic molecules perforin and granzyme-B.39 Additionally,
PD-1 inhibition increases DC expression of the costimulatory molecules, CD40, CD80, and CD86,43 which may
be due to increased MAPK signaling.41 The above studies
demonstrate that PD-1 regulates DC function both
directly and indirectly within the inflammatory TME.
In some models, anti-
PD-1 efficacy indirectly requires
components of the non-canonical NF-κB pathway, and in
others, anti-PD-1 directly drives upregulation of components such as CD40. Thus, multiple lines of evidence
suggest the combination of CD40 agonists and anti-PD-1
as a means of improving antitumor immunity and overcoming checkpoint resistance.
DC-specific effects of PD-L1 blockade
Anti-PD-L1 therapy is now employed to treat numerous
solid tumor types; however, the mechanism of action
still remains debated. One clue toward this mechanism
is the recent observation that expression of PD-L1 by
intratumoral immune infiltrate is a better correlate
to anti-
PD-
L1 clinical response than tumor expressed
specific transcriptomic
PD-L1.4444 Interestingly, a DC-
signature, calculated from the expression levels of XCR1,
BATF3, IRF8, and Flt3, stratified anti-PD-L1-treated renal
cell carcinoma and lung cancer patients into long-term
and short-term survivors, suggesting that DC-expressed
PD-L1 may be a primary target of successful anti-PD-L1
therapy.45 PD-L1 is widely expressed in DC subsets, with
increased expression in the setting of inflammation and
cancer.45 46 DC-
expressed PD-
L1 acts as a homeostatic
control of autoimmunity and directly restrains highly
active T cell responses.47 In two recent publications,
researchers sought to study the contribution of DCs to
5
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tumor and tumor immune infiltrate PD-L1 expression;
and differing cancer types may have divergent biology
herein.
The portrait of myeloid PD-L1 engagement is further
complicated by in vitro evidence that PD-L1 can have
intrinsic signaling of its own. When engaged, PD-L1 can
induce proliferation, costimulatory molecule expression,
cytokine production, and mTOR signaling in macrophages.33 It is noteworthy that TAMs can express both
PD-
L1 and its ligands PD-1 and B7.1 (CD80), which
have sufficient affinity to interact in cis.34 The evidence
presented above suggests that PD-L1 inhibitors may have
intrinsic effects on myeloid cells by either preventing
direct engagement in trans or disrupting cis interactions.
Further research is needed to elucidate the primary
mode of myeloid specific anti-PD-L1 efficacy. Potential
modalities include inhibition of PD-1 engagement on
myeloid cells, disruption of myeloid PD-L1 engagement
with T cell PD-1 or inhibition of direct signaling through
myeloid PD-L1. Regardless of the primary modality, it is
increasingly appreciated that blocking PD-L1 may have
a very different outcome compared with blocking PD-1.
Indeed, in a model of pancreatic cancer, the combination
of PD-1 and PD-L1 confer a synergistic benefit over either
therapy alone.35 Based on the essential role of PD-1/
PD-L1 in myeloid cells, it is likely that the success of anti-
PD-L1 and anti-PD-1 combined therapy relies both on
the disruption of immunosuppressive TAM-T cell crosstalk and on directly reshaping TAM phenotype toward an
antitumor profile.

Open access

The complex role of MDSCs in PD-1/PD-L1 blockade
MDSCs are a heterogeneous group of relatively immature myeloid cells, which can play an immunosuppressive
role in multiple cancers.52 53 The effects of PD-1/PD-L1
blockade on MDSCs are multifaceted and represent a
double-
edged sword because they may simultaneously
induce antitumor immunity and promote tolerance.
Indirect regulation
While anti-PD-1/PD-L1 therapies have shown potential
to induce antitumor myeloid activity, they can also have
complex protumorigenic outcomes, such as recruiting
immunosuppressive MDSCs.54 Circulating MDSCs are
associated with poor survival in patients with melanoma
who have received checkpoint therapy.53 The frequency
of tumor-infiltrating MDSCs is significantly elevated in
metastatic melanoma biopsies obtained from patients
receiving anti-
PD-1 therapy.55 This recruitment may
be driven by anti-PD-1-activated T cells secreting IFN-γ,
which partially triggers the tumor-
intrinsic NLRP3
inflammasome.54 NLRP3 activity drives CXCL5-mediated
6

recruitment of granulocytic MDSCs.54 Thus, anti-
PD-1
therapy can lead to anti-PD-1 resistance, in an apparent
negative feedback loop. In addition to IFN-γ, checkpoint-
activated CD8+ T cells secrete more TNF-α, both of which
lead to tumor production of CSF1. CSF1, in turn, induces
the differentiation and survival of protumorigenic TAMs
and MDSCs, thus magnifying checkpoint resistance.56
Based on these data, one clear strategy to improve
checkpoint efficacy is to limit the infiltration of MDSCs.
Indeed, in models of pancreatic cancer, colon cancer,
and breast cancer, blockade of CXCR2 suppresses the
recruitment of MDSCs, triggering antitumor immunity,
increasing T cell numbers, and sensitizing tumors to anti-
PD-1 therapy.57 The above studies clearly demonstrate
that PD-1/PD-
L1 checkpoint blockade may indirectly
drive checkpoint resistance by expanding and recruiting
MDSCs. Treatment of multiple solid tumors may benefit
from combining checkpoint therapy with targeted strategies to limit MDSC chemotaxis.
Direct regulation
MDSCs may express both PD-1 and PD-L1, which can
lead to a reversal of MDSC-related immunosuppression
when targeted by checkpoint blockade.58–60 As with other
myeloid lineages, MDSC expression of PD-1 and PD-L1
is inducible in inflammatory settings.58 Activated T cells
may promote MDSC expression of PD-L1 through the
IFN-γ−IFNGR1−STAT1−IRF1 axis.59 MDSCs with high
expression of PD-1/PD-
L1 demonstrate high rates of
proliferation, leading to their robust expansion in the
TME of many cancers.58 The joint expression of PD-1 and
PD-L1 by MDSCs suggests that both anti-PD-1 and anti-
PD-L1 should be evaluated for their MDSC remodeling
potential. Indeed, in a model of multiple myeloma, joint
therapy with anti-PD-1 and anti-PD-L1 prevented MDSC-
mediated cancer promotion to a greater extent than either
alone.60 In contrast to cancers such as melanoma, head and
neck squamous cell carcinoma (HNSCC) demonstrates
reduced granulocytic MDSC infiltration post-PD-1/PD-L1
blockade.61 It is unclear whether this model involves
different mechanisms of MDSC recruitment or whether
the direct blockade of PD-1 is inhibiting MDSC proliferation. Antagonism of PD-L1 in MDSCs has been shown
to reduce the immunosuppressive polarization of T cells.
In coculture experiments, treatment of MDSCs with anti-
PD-L1 led to increased rates of T cell proliferation and
IFN-γ production, which may be an outcome of reduced
IL6 and IL10 production.62 63 The studies discussed above
highlight the nuanced and complex effects of checkpoint
therapy on MDSCs. PD-1/PD-L1 blockade can improve
outcomes via a direct reversal of MDSC-related immunosuppression, while synchronously driving checkpoint
resistance through MDSC recruitment.
Innate lymphocytes and PD-1/PD-L1 blockade
Recent studies have identified innate lymphocytes as novel
targets of checkpoint inhibitors.64 65 Innate lymphocytes
are divided into two large branches: natural killer (NK)
Liu X, et al. J Immunother Cancer 2021;9:e001460. doi:10.1136/jitc-2020-001460
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anti-PD-L1 therapy by conditionally deleting PD-L1.48 49 In
both cases, selective ablation of PD-L1 on DCs restricted
tumor growth as effectively as systemic PD-L1 knockout
mice, indicating that DCs are likely critical to the reinvigorated T cell response after anti-PD-L1 immunotherapy.48 49
At early timepoints, DC-specific PD-L1 deletion led to
enhanced tumor infiltration of effector CD8+ T cells, but
not proliferation, indicating there may be increased T cell
recruitment.48 These findings highlight that checkpoint-
responsive patients may be best identified by measuring
DC expression of PD-L1 rather than tumor expression.
Aside from the classical PD-1/PD-
L1 axis, APC-
expressed PD-L1 can also bind the costimulatory molecule
B7.1 (CD80) in cis with higher affinity than the canonical
T cell costimulatory receptor CD28.34 Consequently, T
cell immunity may be suppressed by both the PD-L1−B7.1
and the PD-L1−PD1 axes, either by directly dampening
TCR signaling or by restricting a necessary costimulatory
signal.50 In two recent publications, researchers reached
differing conclusions as to whether blocking PD-L1’s cis
interaction enhances CD28 signaling.45 48 Disrupting the
PD-
L1−B7.1 interaction may in fact accelerate tumor
growth by permitting PD-L1/PD-1 engagement; however,
this observation was accompanied by a significant increase
in intratumoral T cell numbers, indicating that enhanced
priming via CD28-B7.1 may have also occurred.48 Further
research is needed to clarify the role of cis PD-L1−B7.1
binding on DCs, and whether DC-specific PD-L1 engages
PD-1 expressed by other myeloid subsets such as TAMs.
DCs are uniquely specialized APCs that efficiently prime
naive T cell responses.51 The evidence above demonstrates that DCs are critical for anti-PD-L1 efficacy. Thus,
PD-L1 blockade may offer a targeted approach to improve
DC-mediated priming of antitumor T cell responses, by
both releasing B7.1 and disinhibiting downstream TCR
activation.
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NK cells
Solid tumors, such as renal cell carcinoma, can be heavily
infiltrated by NK cells.66 These innate lymphocytes are
regulated by constitutively expressed activating and inhibitory receptors, which recognize stress-induced ligands
and various conserved motifs on class I and non-canonical
MHC molecules.68 There are conflicting reports as to
whether NK cells express significant levels of PD-1. Some
groups suggest that neither mouse nor human NK cells
express PD-1;69 however, other groups have reported
PD-1 expressing NK cells in several cancer types.70 It is
likely that PD-1 is expressed by NK cells in certain inflammatory conditions. Tumor-
educated NK cells upregulate PD-1, which, when engaged by PD-L1, dampens NK
cell-mediated antitumor immunity.71 Emerging evidence
suggests that PD-1/PD-L1 blockade increases both NK cell
recruitment and cytotoxicity against multiple myeloma
cells.64 Additionally, anti-PD-1 therapy is capable of triggering NK cell activation and production of IFN-γ.72 To
further complicate matters, NK cells may express PD-L1,
which induces enhanced antitumor functionality when
agonized.73 In vivo studies suggest that the use of anti-
PD-
L1 not only blocks negative PD-1 engagement on
NK cells, but also activates PD-L1+ NK cells, leading to
enhanced tumor rejection.73 Although NK cells likely
represent an additional target of PD-1/PD-L1 blockade,
additional research is needed to determine whether NK
cell-specific PD-1/PD-L1 blockade is clinically relevant in
solid tumors, and whether a physiological role exists for
PD-L1 signaling in these innate immune cells.
Innate lymphoid cells
Checkpoint inhibitors are also capable of reshaping ILC
responses in pathological conditions such as cancer.74
While high PD-1 expression on ILC progenitors is lost
on differentiation, PD-1 levels may be upregulated in
response to tissue-specific cues. PD-1 is upregulated in
tissue-resident ILC2s in the context of lung inflammation.75 The depletion of PD1high effector ILC2s reduces
inflammation during influenza and allergen exposure.75
Expression of PD1 on ILCs is also relevant for antitumor immunity. Tumor-infiltrating ILC2s (TILC2s) are
predictive of long-term survival in patients with pancreatic cancer.76 TILC2s express significant levels of PD-1,
and TILC2 density increases post-
anti-
PD-1 therapy.76
In an orthotopic model of pancreatic cancer, TILC2s
Liu X, et al. J Immunother Cancer 2021;9:e001460. doi:10.1136/jitc-2020-001460

deficient hosts were
adoptively transferred into ILC2-
partially responsible for the reduction in tumor burden
post-anti-PD-1 therapy.76 In addition to ILC2s, ILC3s are
also affected by checkpoint therapies. ILC3s express PD-1
in primary and metastatic tumors,65 and the PD-1/PD-L1
axis in ILC3s regulates cytokines secretion and immune
tolerance.77 Although still in its early stages, research into
the role of ILCs during checkpoint therapy represents a
promising new field for cancer immunotherapy.
The impact of CTLA-4 blockade on innate immune cells
Although CTLA-4 expression is largely restricted to T cell
lineages and some cancers, there are numerous indirect
effects of anti-CTLA-4 therapy on innate immune subsets.
Anti-CTLA-4 blockade reduces the numbers of tumor-
infiltrating MDSCs and protumorigenic TAMs in a spontaneous model of HNSCC.78 In addition, patients with
advanced melanoma treated with anti-
CTLA-4 exhibit
decreased intratumoral MDSC numbers with a reversal
in their tolerogenic profiles.79 As mentioned previously,
Gubin et al demonstrated the ability of checkpoint
blockade, including anti-CTLA-4 therapy, to reshape the
myeloid compartment.10 Anti-CTLA-4 therapy indirectly
polarizes TAMs, in an IFN-γ-dependent process, toward
an antitumor phenotype characterized by the increased
expression of NF-κB-related genes.10 Of note, a recent
publication demonstrated that the efficacy of human anti-
CTLA-4 was partially attributable to the Fc portion of the
antibody and it’s affinity to Fcγ-receptors such as CD32a,
expressed by multiple innate subsets.80 Treatment with
anti-CTLA-4 resulted in depletion of CTLA-4 expressing
Tregs, highlighting an additional role of innate subsets
responsible for antibody-dependent-cellular cytotoxicity
during checkpoint blockade.80 However, these effects
may be highly dependent on the IgG class of the CTLA-4
targeting antibody. There is more limited evidence for
the direct engagement of CTLA-4 on innate immune
lineages. Subsets of tumor-infiltrating NK cells express
CTLA-4 and CD28, and CTLA-4 blockade was found to
inhibit IFN-γ release by NK cells on coculture with mature
DCs.81 In summary, like anti-PD1/PD-L1 therapies, anti-
CTLA-4 therapy is capable of inducing global shifts in
tumor-infiltrating innate immune subsets. Reports of the
expression of CTLA-4 and CD28 in tumor-
infiltrating
NK cells suggest that further efforts are needed to assess
whether the NK cell-
specific effects of anti-
CTLA-4
blockade have been misattributed to T cells.
Emerging checkpoints inhibitors and their impact on innate
immune cells
The clinical success of checkpoint therapies targeting
PD-1/PD-
L1 and CTLA-4 spurred intense interest in
identifying additional coinhibitory and costimulatory
receptors as potential therapeutic targets. After PD-1 and
CTLA-4, lymphocyte-activation gene 3 (LAG3) was the
third inhibitory receptor to be clinically targeted.82 In
lymphoid lineages, LAG3 is highly expressed in activated
T cells, Tregs, and NK cells.82 In myeloid subsets, LAG3
7
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cells and innate lymphoid cells (ILCs). ILCs are further
divided into ILC1s, ILC2s, ILC3s, and lymphoid tissue-
inducer (LTi) cells.66 NK cells functionally mirror CD8+ T
cells because they exhibit antitumor cytotoxic activity. In
comparison, ILC subsets are tissue-resident populations
with analogous roles to CD4+ T helper (Th) cell subsets.
ILC1s produce IFN-γ to control intracellular pathogens,
ILC2s produce IL-4, IL-5, and IL-13 to target parasites,
and ILC3s secrete IL-17 and IL-22 to defend against extracellular bacteria and fungi.67 LTi cells are critical for the
formation of secondary lymphoid tissues.67
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improves antitumor DC-
T cell crosstalk by enhancing
cross-presentation by CD103+ DCs,91 and increasing DC
expression of CXCL9, a T cell chemoattractant.97 Interestingly, in a fibrosarcoma model, DCs were required
for anti-
TIM3-
enhanced chemotherapy efficacy. These
results suggest that TIM3 may inhibit DC activation,
antigen presentation, and DC crosstalk in the setting of
chemotherapy-induced immunogenic cell death.96 Taken
together, TIM3’s wide expression in innate and adaptive subsets, and its demonstrated role in the crosstalk
between the two, highlight TIM3 as a promising immunotherapeutic target. The emergence of novel coinhibitory receptors will necessitate careful evaluation of which
targets synergize with existing checkpoint therapies and
broadly enhance antitumor immunity in both innate and
adaptive compartments.

CONCLUSIONS
The studies highlighted in this review paint a complex
picture of the relationship between checkpoint blockade
and innate immunity. Myeloid cells and innate lymphocytes contribute to both checkpoint efficacy and resistance, through both direct and indirect mechanisms.
The challenge for researchers and clinicians is to balance
the varied, and sometimes opposing, effects of checkpoint therapies, so that they may intelligently employ and
combine immunotherapies in the fight against cancer.
Shifting the focus of checkpoint blockade from ‘T cell
centrism’ to a more holistic view of the complex and
interconnected TME may reveal new opportunities to
broaden the benefits of checkpoint blockade to the many
patients in need of prognosis-altering therapies.
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